EyePoint Pharmaceuticals

EyePoint Pharmaceuticals

生物技术研究

Watertown,MA 13,289 位关注者

Delivering Innovation to the Eye? NOW HIRING!

关于我们

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert? technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Durasert’s proven intravitreal drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA-approved products, including YUTIQ? for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

网站
https://www.eyepointpharma.com
所属行业
生物技术研究
规模
51-200 人
总部
Watertown,MA
类型
上市公司
领域
Ophthalmology、Glaucoma、WetAMD、Optometry、Eye Disease和Retinal Disease

地点

  • 480 Pleasant St., Suite B300

    US,MA,Watertown,02472

    获取路线

EyePoint Pharmaceuticals员工

动态

关联主页

相似主页

查看职位

融资